In recent years, Adipose-Derived Stromal Cells (ADSCs) have emerged as a potent source of therapeutic cells for the treatment of various clinical indications. This review focusses on ADSCs as a product and the current clinical trial landscape of ADSCs. In-depth emphasis has been given for the clinical and conceptual framework of ADSCs to treat ischemic based indications such as Inflammatory Bowel Dieseases, Cerebrovascular Diseases, Chronic Obstructive
No takes yet. Share an insight, caveat, or question.
NK et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: